<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Malar J</journal-id>
      <journal-title>Malaria Journal</journal-title>
      <issn pub-type="epub">1475-2875</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">12057021</article-id>
      <article-id pub-id-type="pmc">111499</article-id>
      <article-id pub-id-type="publisher-id">1475-2875-1-1</article-id>
      <article-id pub-id-type="doi">10.1186/1475-2875-1-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Malarone treatment failure and <italic>in vitro</italic> confirmation of resistance of <italic>Plasmodium falciparum</italic> isolate from Lagos, Nigeria</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" corresp="yes" contrib-type="author">
          <name>
            <surname>Fivelman</surname>
            <given-names>Quinton L</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>quinton.fivelman@lshtm.ac.uk</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Butcher</surname>
            <given-names>Geoffrey A</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>g.butcher@ic.ac.uk</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Adagu</surname>
            <given-names>Ipemida S</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ipemida.adagu@lshtm.ac.uk</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>Warhurst</surname>
            <given-names>David C</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>david.warhurst@lshtm.ac.uk</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Pasvol</surname>
            <given-names>Geoffrey</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>g.pasvol@ic.ac.uk</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK</aff>
      <aff id="I2"><label>2</label>Department of Biology, Sir Alexander Fleming Building, Impeial College, Imperial College Road, London, SW7 2AZ, UK</aff>
      <aff id="I3"><label>3</label>Department of Infection and Tropical Medicine, Faculty of Medicine, Imperial College, Lister Unit, Northwick Park Hospital, Harrow, Middlesex, HA1 3UJ, UK</aff>
      <pub-date pub-type="collection">
        <year>2002</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>2</month>
        <year>2002</year>
      </pub-date>
      <volume>1</volume>
      <fpage>1</fpage>
      <lpage>1</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/1/1/1"/>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>12</month>
          <year>2001</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>2</month>
          <year>2002</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2002 Fivelman et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement>
        <copyright-year>2002</copyright-year>
        <copyright-holder>Fivelman et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder>
      </permissions>
      <abstract>
        <p>We report the first <italic>in vitro</italic> and genetic confirmation of Malarone<sup>&#xAE;</sup> (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in <italic>Plasmodium falciparum</italic> acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone<sup>&#xAE;</sup>. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome <italic>b</italic> gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Increasing reports of drug-resistant <italic>P. falciparum</italic> throughout the world have forced changes in both prevention and treatment. Malarone<sup>&#xAE;</sup> (GlaxoSmithKline; atovaquone and proguanil hydrochloride) is a recently introduced new drug combination for the treatment [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>] and prophylaxis [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>] of falciparum malaria. We report the first <italic>in vitro</italic> and genetic confirmation of Malarone<sup>&#xAE;</sup> resistance in a case of <italic>P. falciparum</italic> acquired in Africa.</p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A forty-five year old Nigerian male, resident in the UK, presented with a fever and 1.5% <italic>P. falciparum</italic> parasitaemia two weeks after returning from a 4-week visit to Lagos, Nigeria without taking prophylaxis. The patient was given a standard 3-day treatment course of Malarone<sup>&#xAE;</sup>; four tablets daily (one tablet is equivalent to 250 mg of atovaquone and 100 mg of proguanil hydrochloride) with food which he tolerated well without vomiting and was later discharged. Twenty-eight days later, his malaria symptoms returned. After a further five days the patient was readmitted to hospital with a parasitaemia of less than 1 %. A blood sample taken at this point was placed into culture. The patient was successfully treated with quinine 600 mg three times per day for three days followed by doxycycline 100 mg per day for seven days.</p>
      <p>Drug sensitivity assays were performed at 1 % parasitaemia and 1 % haematocrit using tritiated hypoxanthine uptake as a measure of parasite viability [<xref ref-type="bibr" rid="B5">5</xref>] and the isolate (NGATV01) was shown to be resistant to atovaquone (Table <xref ref-type="table" rid="T1">1</xref>). The NGATV01 isolate was also resistant to the antifolate pyrimethamine. The standard laboratory strain K1 was assayed as above and exhibited resistance to both chloroquine and pyrimethamine. The DNA of NGATV01 was extracted and the cytochrome <italic>b</italic> coding region of mitochondrial DNA (mtDNA) sequenced [<xref ref-type="bibr" rid="B6">6</xref>] in both directions together with DNA samples from <italic>P. falciparum</italic> control strains. The sequence showed a change from TAT to AAT in codon 268 (Figure <xref ref-type="fig" rid="F1">1</xref>), specifying a change from tyrosine (Tyr) to asparagine (Asn): Y268N. A different mutation in this codon leading to serine was reported earlier in a sample (TM93-C1088) from an atovaquone and pyrimethamine treatment failure in a Thai patient [<xref ref-type="bibr" rid="B6">6</xref>]</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p>Sequence analysis of <italic>P. falciparum</italic> CYT <italic>b</italic> gene from isolate NGATV01 showing codons 70 to 309. Residue 268 highlighted shows the change from tyrosine (Y) to asparagine (N) compared to atovaquone-sensitive strain K1 and the change to serine (S) in the atovaquone-resistant strain TM93-C1088 [<xref ref-type="bibr" rid="B6">6</xref>].</p>
        </caption>
        <graphic xlink:href="1475-2875-1-1-1"/>
      </fig>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p><italic>In vitro</italic> sensitivity of isolate NGATV01 and strain K1 to standard antimalarial drugs with standard deviations (nmol/L).</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td align="left">
                <bold>Drug</bold>
              </td>
              <td align="center">
                <bold>NGATV01</bold>
              </td>
              <td align="center">
                <bold>K1</bold>
              </td>
              <td align="left">
                <bold>Resistance Cut-off<sup>*</sup></bold>
              </td>
            </tr>
            <tr>
              <td/>
              <td colspan="2">
                <hr/>
              </td>
              <td/>
            </tr>
            <tr>
              <td/>
              <td align="center">
                <bold>Mean IC<sub>50</sub> &#xB1; SD</bold>
              </td>
              <td align="center">
                <bold>Mean IC<sub>50</sub> &#xB1; SD</bold>
              </td>
              <td/>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left">Chloroquine</td>
              <td align="center">9.54 &#xB1; 1.18</td>
              <td align="center">133.29 &#xB1; 30.12</td>
              <td align="left">100</td>
            </tr>
            <tr>
              <td align="left">Mefloquine</td>
              <td align="center">24.14 &#xB1; 5.20</td>
              <td align="center">8.55 &#xB1; 0.29</td>
              <td align="left">20</td>
            </tr>
            <tr>
              <td align="left">Pyrimethamine</td>
              <td align="center">16012.80 &#xB1; 2643.55</td>
              <td align="center">8082.84 &#xB1; 1202.69</td>
              <td align="left">100</td>
            </tr>
            <tr>
              <td align="left">Atovaquone</td>
              <td align="center">1888.15 &#xB1; 106.65</td>
              <td align="center">2.41 &#xB1; 1.01</td>
              <td align="left">20</td>
            </tr>
            <tr>
              <td align="left">Proguanil</td>
              <td align="center">4205.50 &#xB1; 716.99</td>
              <td align="center">10239.94 &#xB1; 843.51</td>
              <td align="left">not determined</td>
            </tr>
            <tr>
              <td align="left">Dihydroartemisinin</td>
              <td align="center">2.39 &#xB1; 0.07</td>
              <td align="center">1.26 &#xB1; 0.46</td>
              <td align="left">not determined</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Drug assay was performed at 1 % parasitaemia and 1 % haematocrit. Experiment was repeated twice in duplicate.<sup>*</sup> Cut-off points for resistance as previously reported [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B6">6</xref>]</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>The target of atovaquone, CYT <italic>b</italic>, plays an important role in electron transport during mitochondrial respiration. It is thought that the drug, an analogue of coenzyme Q (ubiquinone), interrupts electron transport and leads to loss of the mitochondrial membrane potential [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Tyr268 is a conserved bulky hydrophobic contact of the drug in the Q<sub>o</sub> II region of the ubiquinol oxidation site. Substitution of the less bulky Asn268 should affect the fit and binding of the drug (Figure <xref ref-type="fig" rid="F2">2</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2</label>
        <caption>
          <p>Atovaquone (ATV) in <italic>P. falciparum</italic> cytochrome <italic>b</italic> active site. <bold>A</bold>: Atovaquone built and docked using HyperChem release 6, in the active site of a model of <italic>P. falciparum</italic> cytochrome B. Homology model prepared using the structure of the chicken enzyme [<xref ref-type="bibr" rid="B14">14</xref>] with the aid of the SWISS-MODEL Protein Modelling Server and observed in the Swiss Model Viewer [<xref ref-type="bibr" rid="B15">15</xref>]. <bold>B</bold>: As A, with active site tyrosine268 replaced by asparagine.</p>
        </caption>
        <graphic xlink:href="1475-2875-1-1-2"/>
      </fig>
      <p>Resistance rapidly emerges when atovaquone is used alone [<xref ref-type="bibr" rid="B9">9</xref>]. It has been hypothesised that the mode of action of the drug might contribute to the rapid appearance of resistant parasites. During a stage in its interaction with the site when the drug is partially oxidised, the semiquinone formed would be capable of forming reactive oxygen species (ROS) capable of acting as local mutagens during replication of the mtDNA. Proguanil is believed to speed the loss of the membrane potential, and ensure that replication of DNA stops before mutagenesis can occur [<xref ref-type="bibr" rid="B10">10</xref>].</p>
    </sec>
    <sec>
      <title>Conclusions</title>
      <p>This is an unusual example of resistance detected during a single course of Malarone<sup>&#xAE;</sup> on only a moderate parasitaemia. The atovaquone/proguanil combination has not been widely used yet in West Africa so it is unlikely that the patient was initially infected with an atovaquone-resistant strain. The presence of multidrug-resistant strains such as this example raises concern about the recent move to consider using Malarone as first-line therapy in Africa [<xref ref-type="bibr" rid="B11">11</xref>]. The case questions the potential useful life of this combination, especially as atovaquone may persist alone in plasma for up to 6 weeks after treatment [<xref ref-type="bibr" rid="B12">12</xref>]. It appears that the synergistic interaction with proguanil is not seen in atovaquone-resistant mutants [<xref ref-type="bibr" rid="B13">13</xref>], and higher resistance levels are achievable.</p>
    </sec>
  </body>
  <back>
    <ack>
      <sec>
        <title>Acknowledgements</title>
        <p>We thank Dr. Watcharee Chokejindachai and Dr. Jill Curtis of the London School of Hygiene and Tropical Medicine for technical advice and encouragement. Quinton Fivelman was supported by the Association of Commonwealth Universities and David Warhurst thanks UK PHLS for financial support.</p>
      </sec>
    </ack>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Llanos-Cuentas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Clendenes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Canfield</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute <italic>Plasmodium falciparum</italic> malaria in Peru.</article-title>
          <source>Braz J Infect Dis</source>
          <year>2001</year>
          <volume>5</volume>
          <fpage>67</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">11493411</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Looareesuwan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chulay</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Canfield</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>DB</given-names>
            </name>
          </person-group>
          <article-title>Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1999</year>
          <volume>60</volume>
          <fpage>533</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="pmid">10348225</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Overbosch</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schilthuis</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bienzle</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Behrens</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Kain</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>PD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atovaquone-Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travellers: Results from a Randomized, Double-Blind Study.</article-title>
          <source>Clin Infect Dis</source>
          <year>2001</year>
          <volume>33</volume>
          <fpage>1015</fpage>
          <lpage>1021</lpage>
          <pub-id pub-id-type="pmid">11528574</pub-id>
          <pub-id pub-id-type="doi">10.1086/322694</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hogh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Camus</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nothdurft</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Overbosch</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gunther</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>356</volume>
          <fpage>1888</fpage>
          <lpage>1894</lpage>
          <pub-id pub-id-type="pmid">11130385</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(00)03260-8</pub-id>
        </citation>
      </ref>
      <ref id="B5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desjardins</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Canfield</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haynes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chulay</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique.</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1979</year>
          <volume>16</volume>
          <fpage>710</fpage>
          <lpage>718</lpage>
          <pub-id pub-id-type="pmid">394674</pub-id>
        </citation>
      </ref>
      <ref id="B6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Korsinczky</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kotecka</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Saul</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rieckmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>Q</given-names>
            </name>
          </person-group>
          <article-title>Mutations in <italic>Plasmodium falciparum</italic> cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site.</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2000</year>
          <volume>44</volume>
          <fpage>2100</fpage>
          <lpage>2108</lpage>
          <pub-id pub-id-type="pmid">10898682</pub-id>
          <pub-id pub-id-type="doi">10.1128/AAC.44.8.2100-2108.2000</pub-id>
        </citation>
      </ref>
      <ref id="B7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fry</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pudney</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80).</article-title>
          <source>Biochem Pharmacol</source>
          <year>1992</year>
          <volume>43</volume>
          <fpage>1545</fpage>
          <lpage>1553</lpage>
          <pub-id pub-id-type="pmid">1314606</pub-id>
          <pub-id pub-id-type="doi">10.1016/0006-2952(92)90213-3</pub-id>
        </citation>
      </ref>
      <ref id="B8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srivastava</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Rottenberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.</article-title>
          <source>J Biol Chem</source>
          <year>1997</year>
          <volume>272</volume>
          <fpage>3961</fpage>
          <lpage>3966</lpage>
          <pub-id pub-id-type="pmid">9020100</pub-id>
          <pub-id pub-id-type="doi">10.1074/jbc.272.52.33360</pub-id>
        </citation>
      </ref>
      <ref id="B9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Looareesuwan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Viravan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Canfield</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1996</year>
          <volume>54</volume>
          <fpage>62</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">8651372</pub-id>
        </citation>
      </ref>
      <ref id="B10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaidya</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Mather</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>Atovaquone resistance in malaria parasites.</article-title>
          <source>Drug Resist Updat</source>
          <year>2000</year>
          <volume>3</volume>
          <fpage>283</fpage>
          <lpage>287</lpage>
          <pub-id pub-id-type="pmid">11498396</pub-id>
          <pub-id pub-id-type="doi">10.1054/drup.2000.0157</pub-id>
        </citation>
      </ref>
      <ref id="B11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shretta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brugha</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Robb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Snow</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Sustainability, affordability, and equity of corporate drug donations: the case of Malarone.</article-title>
          <source>Lancet</source>
          <year>2000</year>
          <volume>355</volume>
          <fpage>1718</fpage>
          <lpage>1720</lpage>
          <pub-id pub-id-type="pmid">10905260</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(00)02251-0</pub-id>
        </citation>
      </ref>
      <ref id="B12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Butcher</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Mendoza</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sinden</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of the mosquito transmission of <italic>Plasmodium berghei</italic> by Malarone (atovaquone-proguanil).</article-title>
          <source>Ann Trop Med Parasitol</source>
          <year>2000</year>
          <volume>94</volume>
          <fpage>429</fpage>
          <lpage>436</lpage>
          <pub-id pub-id-type="pmid">10983555</pub-id>
        </citation>
      </ref>
      <ref id="B13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Srivastava</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Morrisey</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Darrouzet</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Daldal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Vaidya</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.</article-title>
          <source>Mol Microbiol</source>
          <year>1999</year>
          <volume>33</volume>
          <fpage>704</fpage>
          <lpage>711</lpage>
          <pub-id pub-id-type="pmid">10447880</pub-id>
          <pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01515.x</pub-id>
        </citation>
      </ref>
      <ref id="B14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crofts</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ugulava</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Barquera</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gennis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guergova-Kuras</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pathways for proton release during ubihydroquinone oxidation by the bc(1) complex.</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1999</year>
          <volume>96</volume>
          <fpage>10021</fpage>
          <lpage>10026</lpage>
          <pub-id pub-id-type="pmid">10468555</pub-id>
          <pub-id pub-id-type="doi">10.1073/pnas.96.18.10021</pub-id>
        </citation>
      </ref>
      <ref id="B15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guex</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Diemand</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peitsch</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Protein modelling for all.</article-title>
          <source>Trends Biochem Sci</source>
          <year>1999</year>
          <volume>24</volume>
          <fpage>364</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="pmid">10470037</pub-id>
          <pub-id pub-id-type="doi">10.1016/S0968-0004(99)01427-9</pub-id>
        </citation>
      </ref>
      <ref id="B16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gay</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bustos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Traore</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jardinel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Southammavong</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ciceron</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title><italic>In vitro</italic> response of <italic>Plasmodium falciparum</italic> to atovaquone and correlation with other antimalarials: comparison between African and Asian strains.</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1997</year>
          <volume>56</volume>
          <fpage>315</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="pmid">9129535</pub-id>
        </citation>
      </ref>
      <ref id="B17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basco</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>Ramiliarisoa</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Le Bras</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title><italic>In vitro</italic> activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of <italic>Plasmodium falciparum</italic>.</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1994</year>
          <volume>50</volume>
          <fpage>193</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="pmid">8116812</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
